25 XP   0   0   10

Inozyme Pharma Inc
Buy, Hold or Sell?

Let's analyse Inozyme together

PenkeI guess you are interested in Inozyme Pharma Inc. Buy, hold or sell? I don't know! However, I do recommend doing research before doing anything. I will help you with that.

I'm going to help you getting a better view of Inozyme Pharma Inc. At the end you don't have to ask anyone for trading advice. You can make your own decision, with more confidence, the odds in your favor, backed by data.

You can find me behind Let's Analyse Together in the top-right of each section.

Get notifications about Inozyme Pharma Inc

I send you an email if I find something interesting about Inozyme Pharma Inc.

Quick analysis of Inozyme (30 sec.)










What can you expect buying and holding a share of Inozyme? (30 sec.)

How much money do you get?

How much money do you get?
$0.33
When do you have the money?
1 year
How often do you get paid?
5.9%

What is your share worth?

Current worth
$2.27
Expected worth in 1 year
$2.63
How sure are you?
35.3%

+ What do you gain per year?

Total Gains per Share
$0.68
Return On Investment
9.2%

For what price can you sell your share?

Current Price per Share
$7.39
Expected price per share
$7.01 - $
How sure are you?
50%

1. Valuation of Inozyme (5 min.)




Live pricePrice per Share (EOD)

$7.39

Intrinsic Value Per Share

$-13.17 - $-15.45

Total Value Per Share

$-10.90 - $-13.17

2. Growth of Inozyme (5 min.)




Is Inozyme growing?

Current yearPrevious yearGrowGrow %
How rich?$140.4m$124.1m$3.2m2.6%

How much money is Inozyme making?

Current yearPrevious yearGrowGrow %
Making money-$17.4m-$16.3m-$1.1m-6.8%
Net Profit Margin0.0%0.0%--

How much money comes from the company's main activities?

3. Financial Health of Inozyme (5 min.)




4. Comparing to competitors in the Biotechnology industry (5 min.)




  Industry Rankings (Biotechnology)  


Richest
#322 / 1031

Most Revenue
#771 / 1031

Most Profit
#699 / 1031

Most Efficient
#222 / 1031

What can you expect buying and holding a share of Inozyme? (5 min.)

Welcome investor! Inozyme's management wants to use your money to grow the business. In return you get a share of Inozyme.

What can you expect buying and holding a share of Inozyme?

First you should know what it really means to hold a share of Inozyme. And how you can make/lose money.

Speculation

The Price per Share of Inozyme is $7.39. The market price reflects what other people think it is worth; not what it's really worth. Your job is to find out if the market price is fair, overpriced, or underpriced. I will help you with that.

If you buy blind, there is a 50% chance of making or losing money by selling the stock in the future. However, we can look at a few things to determine the odds in our favor:

  • The fundamentals: the financial health trends of Inozyme.
  • The technials: based on market psychology, we can make a calculated estimate of what the price will do in the future. We can do this through technical analysis. We can calculate the probabilities and the expected value (millionaire math). That's called speculation.
  • The book value: what is the market price compared to it's book value.

Investing

If you really want to invest in Inozyme, you will have to let go of the thought of selling in the future. If you have to sell the share for less than you bought it, it can still be a good investment. Focus on what it means to hold the stock forever:

  • You own a part of the company. The equity of this part can grow or shrink. The current Book Value per Share is $2.27. Based on the TTM, the Book Value Change Per Share is $0.09 per quarter. Based on the YOY, the Book Value Change Per Share is $0.04 per quarter.
  • You may receive quarterly/yearly dividend in the form of additional shares.
  • You may receive quarterly/yearly dividend in the form of cash. Based on the TTM the Dividend per Share is $0.08 per quarter.
Based on historical numbers we can estimate the returns while holding a share of Inozyme.

How much money are you going to get?

 MRQTTMYOY5Y10Y
 $% of Price per Share$% of Price per Share$% of Price per Share$% of Price per Share$% of Price per Share
Usd Eps-0.35-4.7%-0.29-3.9%-0.27-3.7%-0.25-3.3%-0.25-3.3%
Usd Book Value Change Per Share-0.32-4.3%0.091.2%0.040.5%0.131.8%0.131.8%
Usd Dividend Per Share0.000.0%0.081.1%0.000.0%0.020.3%0.020.3%
Usd Total Gains Per Share-0.32-4.3%0.172.3%0.040.5%0.152.1%0.152.1%
Usd Price Per Share4.26-4.94-3.15-7.91-7.91-
Price to Earnings Ratio-3.05--4.39--2.99--8.20--8.20-
Price-to-Total Gains Ratio-13.33-53.68--6.72--17.86--17.86-
Price to Book Ratio1.87-2.54-1.61-3.51-3.51-
Price-to-Total Gains Ratio-13.33-53.68--6.72--17.86--17.86-

When do you get the money?

Usd Investment
$.00
Usd Price Per Share7.39
Number of shares135
Gains per QuarterTrailing 12 Months5 Year
Usd Dividend Per Share0.080.02
Usd Book Value Change Per Share0.090.13
Usd Total Gains Per Share0.170.15
Gains per Quarter (135 shares)23.0520.64
Gains per Year (135 shares)92.1882.57
YearsReturn on Investment (TTM)Return on Investment (5Y)
 DividendBook Value gainTotal gainsDividendBook Value gainTotal gains
Broker costs---10---10
1444882107273
2889717421144156
313214526631217239
417619335841289322
522024145052361405
626429054262433488
730733863472506571
835138672683578654
939543481893650737
10439483910103722820

How sure are you?

Based on the past periods, how sure are you to get value out of your investment.

Linear %
 Trailing 12 Months3Y5 Year10 YearALLTIME
  % % % % %
Earnings Per Share0.04.00.00.0%0.012.00.00.0%0.017.00.00.0%0.017.00.00.0%0.017.00.00.0%
Book Value Change Per Share2.02.00.050.0%3.09.00.025.0%5.012.00.029.4%5.012.00.029.4%5.012.00.029.4%
Dividend per Share1.00.03.025.0%1.00.011.08.3%1.00.016.05.9%1.00.016.05.9%1.00.016.05.9%
Total Gains per Share3.01.00.075.0%4.08.00.033.3%6.011.00.035.3%6.011.00.035.3%6.011.00.035.3%

Fundamentals of Inozyme

About Inozyme Pharma Inc

Inozyme Pharma, Inc., a clinical-stage rare disease biopharmaceutical company, focuses on developing novel therapeutics for the treatment of vasculature, soft tissue, and skeleton diseases. The company's lead product candidate is INZ-701, a soluble, recombinant, genetically engineered, and fusion protein for the treatment of ENPP1 and ABCC6 deficiencies, as well as patients with end-stage kidney disease receiving hemodialysis. It has a license agreement with Yale University for specified therapeutic and prophylactic products. The company was incorporated in 2015 and is headquartered in Boston, Massachusetts.

Fundamental data was last updated by Penke on 2024-03-20 21:21:05.

Financial Health

Profitability Details
 Compared to previous yearCompared to industry
Using its assets, the company is very inefficient in making profit.
Using its investors money, the company is very inefficient in making profit.
Operating Efficiency Details
 Compared to previous yearCompared to industry
Liquidity Details
 Compared to previous yearCompared to industry
The company is very able to pay all its short-term debts.
The company is very able to pay all its short-term debts with the most liquid assets.
Solvency Details
 Compared to previous yearCompared to industry
The company is very able to pay all its debts by selling its assets.
The company is very able to pay all its debts with equity.

Valuation

Valuation Details
 Compared to previous yearCompared to industry
Based on the equity, the company is underpriced.
Based on the earnings, the company is expensive.
Based on how much money comes from the company's main activities, the company is expensive.

1.1. Profitability of Inozyme Pharma Inc.

1.1. Profitability
1.1.1. Net Profit Margin

Measures how much net profit Inozyme earns for each $1 of revenue.

  • Above 10% is considered healthy but always compare Inozyme to the Biotechnology industry mean.
  • A Net Profit Margin of 0.0% means that $0.00 for each $1 in revenue is generated as profit.

Let's take a look of the Net Profit Margin trends of Inozyme Pharma Inc:

  • The MRQ is 0.0%. The data is not here.
Trends
Current periodCompared to+/- 
MRQ-TTM-0.0%
TTM-YOY-0.0%
TTM-5Y-0.0%
5Y-10Y-0.0%
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
MRQ--171.8%+171.8%
TTM--205.8%+205.8%
YOY--262.1%+262.1%
5Y--455.6%+455.6%
10Y--589.0%+589.0%
1.1.2. Return on Assets

Shows how efficient Inozyme is using its assets to generate profit.

  • Above 5% is considered healthy but always compare Inozyme to the Biotechnology industry mean.
  • -10.7% Return on Assets means that Inozyme generated $-0.11 profit for each $1 in assets.

Let's take a look of the Return on Assets trends of Inozyme Pharma Inc:

  • The MRQ is -10.7%. Using its assets, the company is very inefficient in making profit. -2
  • The TTM is -10.1%. Using its assets, the company is very inefficient in making profit. -2
Trends
Current periodCompared to+/- 
MRQ-10.7%TTM-10.1%-0.6%
TTM-10.1%YOY-11.9%+1.8%
TTM-10.1%5Y-11.1%+1.0%
5Y-11.1%10Y-11.1%0.0%
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
MRQ-10.7%-12.5%+1.8%
TTM-10.1%-12.2%+2.1%
YOY-11.9%-11.2%-0.7%
5Y-11.1%-13.4%+2.3%
10Y-11.1%-14.7%+3.6%
1.1.3. Return on Equity

Shows how efficient Inozyme is using its investors money to generate profit.

  • Above 15%-20% is considered healthy but always compare Inozyme to the Biotechnology industry mean.
  • -15.3% Return on Equity means Inozyme generated $-0.15 for each $1 the owners (shareholders) invested.

Let's take a look of the Return on Equity trends of Inozyme Pharma Inc:

  • The MRQ is -15.3%. Using its investors money, the company is very inefficient in making profit. -2
  • The TTM is -14.0%. Using its investors money, the company is very inefficient in making profit. -2
Trends
Current periodCompared to+/- 
MRQ-15.3%TTM-14.0%-1.3%
TTM-14.0%YOY-13.6%-0.4%
TTM-14.0%5Y-11.2%-2.8%
5Y-11.2%10Y-11.2%0.0%
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
MRQ-15.3%-15.8%+0.5%
TTM-14.0%-15.7%+1.7%
YOY-13.6%-13.9%+0.3%
5Y-11.2%-18.3%+7.1%
10Y-11.2%-19.2%+8.0%

1.2. Operating Efficiency of Inozyme Pharma Inc.

1.2. Operating Efficiency
1.2.1. Operating Margin

Measures how efficient Inozyme is operating .

  • Measures how much profit Inozyme makes for each $1 of sales after paying variable costs (production costs, wages, etc) but before taxes.
  • Above 15% is considered healthy but always compare Inozyme to the Biotechnology industry mean.
  • An Operating Margin of 0.0% means the company generated $0.00  for each $1 in revenue (before taxes).

Let's take a look of the Operating Margin trends of Inozyme Pharma Inc:

  • The MRQ is 0.0%. The data is not here.
Trends
Current periodCompared to+/- 
MRQ-TTM-0.0%
TTM-YOY-0.0%
TTM-5Y-0.0%
5Y-10Y-0.0%
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
MRQ--299.1%+299.1%
TTM--210.1%+210.1%
YOY--279.7%+279.7%
5Y--459.9%+459.9%
10Y--596.9%+596.9%
1.2.2. Operating Ratio

Measures how efficient Inozyme is keeping operating costs low.

  • Below 1 is considered healthy (always compare to Biotechnology industry mean).
  • An Operation Ratio of 0.00 means that the operating costs are $0.00 for each $1 in net sales.

Let's take a look of the Operating Ratio trends of Inozyme Pharma Inc:

  • The MRQ is 0.000. The data is not here.
Trends
Current periodCompared to+/- 
MRQ-TTM-0.000
TTM-YOY-0.000
TTM-5Y-0.000
5Y-10Y-0.000
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
MRQ-2.861-2.861
TTM-3.193-3.193
YOY-3.615-3.615
5Y-5.560-5.560
10Y-7.396-7.396

1.3. Liquidity of Inozyme Pharma Inc.

1.3. Liquidity
1.3.1. Current Ratio

Measures if Inozyme is able to pay off Short-term Debt.

  • Above 1.5 is considered healthy (always compare to Biotechnology industry mean).
  • A Current Ratio of 13.36 means the company has $13.36 in assets for each $1 in short-term debts.

Let's take a look of the Current Ratio trends of Inozyme Pharma Inc:

  • The MRQ is 13.363. The company is very able to pay all its short-term debts. +2
  • The TTM is 13.069. The company is very able to pay all its short-term debts. +2
Trends
Current periodCompared to+/- 
MRQ13.363TTM13.069+0.295
TTM13.069YOY10.697+2.372
TTM13.0695Y13.698-0.629
5Y13.69810Y13.6980.000
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
MRQ13.3633.986+9.377
TTM13.0694.440+8.629
YOY10.6975.552+5.145
5Y13.6986.158+7.540
10Y13.6986.492+7.206
1.3.2. Quick Ratio

Measures if Inozyme is able to pay off Short-term Debt but only using the most liquid assets.

  • Above 1 is considered healthy but always compare Inozyme to the Biotechnology industry mean.
  • A Quick Ratio of 23.35 means the company can pay off $23.35 for each $1 in debt (using most liquid assets).

Let's take a look of the Quick Ratio trends of Inozyme Pharma Inc:

  • The MRQ is 23.354. The company is very able to pay all its short-term debts with the most liquid assets. +2
  • The TTM is 21.911. The company is very able to pay all its short-term debts with the most liquid assets. +2
Trends
Current periodCompared to+/- 
MRQ23.354TTM21.911+1.443
TTM21.911YOY17.359+4.552
TTM21.9115Y22.246-0.335
5Y22.24610Y22.2460.000
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
MRQ23.3543.638+19.716
TTM21.9114.168+17.743
YOY17.3595.515+11.844
5Y22.2466.012+16.234
10Y22.2466.209+16.037

1.4. Solvency of Inozyme Pharma Inc.

1.3. Liquidity
1.4.1. Debt to Asset Ratio

Measures how much % of Inozyme assets are financed with debt.

  • Below 1 (100%) is considered healthy but always compare Inozyme to Biotechnology industry mean.
  • A Debt to Asset Ratio of 0.30 means that Inozyme assets are financed with 30.1% credit (debt) and the remaining percentage (100% - 30.1%) is financed by its owners/shareholders. 

Let's take a look of the Debt to Asset Ratio trends of Inozyme Pharma Inc:

  • The MRQ is 0.301. The company is very able to pay all its debts by selling its assets. +2
  • The TTM is 0.273. The company is very able to pay all its debts by selling its assets. +2
Trends
Current periodCompared to+/- 
MRQ0.301TTM0.273+0.027
TTM0.273YOY0.122+0.151
TTM0.2735Y0.325-0.052
5Y0.32510Y0.3250.000
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
MRQ0.3010.335-0.034
TTM0.2730.330-0.057
YOY0.1220.267-0.145
5Y0.3250.367-0.042
10Y0.3250.378-0.053
1.4.2. Debt to Equity Ratio

Measures if Inozyme is able to pay off its debts by using shareholders equity.

  • Below 2 is considered healthy but always compare Inozyme to the Biotechnology industry mean.
  • A Debt to Equity ratio of 43.0% means that company has $0.43 debt for each $1 in shareholders equity.

Let's take a look of the Debt to Equity Ratio trends of Inozyme Pharma Inc:

  • The MRQ is 0.430. The company is very able to pay all its debts with equity. +2
  • The TTM is 0.379. The company is very able to pay all its debts with equity. +2
Trends
Current periodCompared to+/- 
MRQ0.430TTM0.379+0.051
TTM0.379YOY0.140+0.239
TTM0.3795Y0.156+0.223
5Y0.15610Y0.1560.000
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
MRQ0.4300.376+0.054
TTM0.3790.398-0.019
YOY0.1400.334-0.194
5Y0.1560.429-0.273
10Y0.1560.476-0.320

2. Market Valuation of Inozyme Pharma Inc

2.1. Earnings Per Share
2.1. Price to Earnings Ratio

Measures how much money you pay for each share for every $1 in earnings Inozyme generates.

  • Above 15 is considered overpriced but always compare Inozyme to the Biotechnology industry mean.
  • A PE ratio of -3.05 means the investor is paying $-3.05 for every $1 in earnings.

Let's take a look of the Price to Earnings Ratio trends of Inozyme Pharma Inc:

  • The EOD is -5.297. Based on the earnings, the company is expensive. -2
  • The MRQ is -3.054. Based on the earnings, the company is expensive. -2
  • The TTM is -4.389. Based on the earnings, the company is expensive. -2
Trends
Current periodCompared to+/- 
EOD-5.297MRQ-3.054-2.244
MRQ-3.054TTM-4.389+1.335
TTM-4.389YOY-2.993-1.397
TTM-4.3895Y-8.203+3.814
5Y-8.20310Y-8.2030.000
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
EOD-5.297-2.643-2.654
MRQ-3.054-2.418-0.636
TTM-4.389-2.742-1.647
YOY-2.993-4.123+1.130
5Y-8.203-6.257-1.946
10Y-8.203-6.478-1.725
2.2. Price To Free Cash Flow Ratio

Let's take a look of the Price To Free Cash Flow Ratio trends of Inozyme Pharma Inc:

  • The EOD is -6.138. Based on how much money comes from the company's main activities, the company is expensive. -2
  • The MRQ is -3.538. Based on how much money comes from the company's main activities, the company is expensive. -2
  • The TTM is -4.358. Based on how much money comes from the company's main activities, the company is expensive. -2
Trends
Current periodCompared to+/- 
EOD-6.138MRQ-3.538-2.600
MRQ-3.538TTM-4.358+0.820
TTM-4.358YOY-3.337-1.021
TTM-4.3585Y-10.046+5.688
5Y-10.04610Y-10.0460.000
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
EOD-6.138-3.244-2.894
MRQ-3.538-2.939-0.599
TTM-4.358-3.478-0.880
YOY-3.337-5.592+2.255
5Y-10.046-8.473-1.573
10Y-10.046-8.881-1.165
2. Book Value per Share
2.3. Price to Book Ratio

Measures if the stock price of Inozyme is to cheap or to expensive compared to its book value.

  • At or below 1 is considered healthy (always compare to Biotechnology industry mean).
  • A PB ratio of 1.87 means the investor is paying $1.87 for each $1 in book value.

Let's take a look of the Price to Book Ratio trends of Inozyme Pharma Inc:

  • The EOD is 3.250. Based on the equity, the company is fair priced.
  • The MRQ is 1.873. Based on the equity, the company is underpriced. +1
  • The TTM is 2.544. Based on the equity, the company is underpriced. +1
Trends
Current periodCompared to+/- 
EOD3.250MRQ1.873+1.376
MRQ1.873TTM2.544-0.671
TTM2.544YOY1.608+0.936
TTM2.5445Y3.512-0.968
5Y3.51210Y3.5120.000
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
EOD3.2502.124+1.126
MRQ1.8732.041-0.168
TTM2.5442.118+0.426
YOY1.6082.915-1.307
5Y3.5123.682-0.170
10Y3.5124.114-0.602
2. Total Gains per Share

3. Holders & Insider Transactions

Let's take a look at which institutions, funds and insiders are holding shares of Inozyme Pharma Inc.

3.1. Institutions holding Inozyme Pharma Inc

Institutions are holding 92.774% of the shares of Inozyme Pharma Inc.

DateNameTotal SharesTotal AssetsCurrent SharesChange%
2023-12-31Adage Capital Partners Gp LLC8.96610.0488553750000
2023-12-31Pivotal bioVenture Partners Investment Advisor LLC7.27784.8573449485100
2023-12-31Sofinnova Ventures6.93051.0203428030800
2023-12-31Rock Springs Capital Management LP5.96040.386368117400
2023-12-31Samlyn Capital, LLC5.46070.286133725581273503.9242
2023-12-31Eventide Asset Management, LLC5.14860.22113179837548371.7548
2023-12-31BlackRock Inc4.9260.0003304233080258835.8339
2023-12-31NEA Management Company, LLC3.9470.6921243768900
2023-12-31Vanguard Group Inc3.86170.000223850221089374.7862
2023-12-31FMR Inc3.67920.00072272306-192926-7.8259
2023-12-31Affinity Asset Advisors, LLC3.05341.4672188580250595036.667
2023-12-31Sphera Funds Management Ltd.2.53061.0716156290732800026.5607
2023-12-31Samsara BioCapital, LLC2.52991.0355156250000
2023-09-30Octagon Capital Advisors LP2.10490.8388130000012502982515.5889
2023-12-31Blue Owl Capital Holdings LP2.05641.2933127002712700270
2023-09-30CHI Advisors LLC2.05642.11411270027750006.276
2023-12-31Geode Capital Management, LLC1.67210.0005103271620989325.5089
2023-12-31Millennium Management LLC1.47580.0017911465-415406-31.3072
2023-12-31State Street Corporation1.20870.000274653311818618.809
2023-12-31Goldman Sachs Group Inc1.17670.00037267446728561248.6194
Total 76.022915.336146952296+4915590+10.5%

3.2. Funds holding Inozyme Pharma Inc

DateNameTotal SharesTotal AssetsCurrent SharesChange%
2023-12-31Eventide Healthcare & Life Sciences I5.1480.81273179837548371.7548
2024-01-31Fidelity Select Biotechnology3.67040.2703226718700
2024-02-29Vanguard Total Stock Mkt Idx Inv2.18920.0006135225800
2024-02-29iShares Russell 2000 ETF1.85890.01171148210-188-0.0164
2024-02-29Vanguard Institutional Extnd Mkt Idx Tr1.10030.004267965100
2023-12-31Fidelity Small Cap Index0.76550.007947284213982041.9852
2024-02-01iShares Russell 2000 Value ETF0.72510.02144478635660.1265
2023-12-31Kennedy Micro Cap0.46520.25832873772873770
2024-01-31Fidelity Extended Market Index0.40930.003925285000
2024-02-29State St Russell Sm/Mid Cp® Indx NL Cl C0.39870.0038246300135005.799
2024-02-29Vanguard Russell 2000 ETF0.28070.0116173356135288.4641
2023-12-31NT R2000 Value Index Fund - NL0.21930.01531354863921240.7296
2023-12-31NT R2000 Index Fund - NL0.21780.00791345263905940.9136
2024-02-29State St Russell Sm Cap® Indx SL Cl I0.2020.008412480000
2024-01-31Schwab Small Cap Index0.17930.010711077100
2024-02-29iShares Micro-Cap ETF0.17370.074910726500
2023-12-31NT R2000 Index Fund - DC - NL - 20.17150.00791059403046940.3718
2023-09-30BlackRock Extended Mkt Composite0.1710.00311055964452472.9041
2023-12-31Northern Trust Russell 2000 Value Index0.15490.0157956593117648.3476
2023-12-31NT R2000 Value Index Fund - L0.15490.0156956593117648.3476
Total 18.65571.565911523433+725056+6.3%

3.3. Insider Transactions

Insiders are holding 0.652% of the shares of Inozyme Pharma Inc.

DateOwnerTypeAmountPricePost Transaction AmountLink
2023-08-01Pivotal Bioventure Partners FuBUY8333334.8
2023-05-11Robert Lorne HopfnerBUY2192306.48
2023-03-29Robert Lorne HopfnerBUY3445924.54
2023-03-27Robert Lorne HopfnerBUY510743.7

4. Summary

4.1. Key Performance Indicators

The key performance indicators of Inozyme Pharma Inc compared to the Most Recent Quarter (MRQ).

 End of day+/-Most Recent QuarterTrailing 12 Months+/-Year-Over-Year+/-5 Year+/-10 Year+/-
Book Value Change Per Share---0.3190.089-457%0.037-965%0.134-339%0.134-339%
Book Value Per Share--2.2742.063+10%2.010+13%1.754+30%1.754+30%
Current Ratio--13.36313.069+2%10.697+25%13.698-2%13.698-2%
Debt To Asset Ratio--0.3010.273+10%0.122+146%0.325-8%0.325-8%
Debt To Equity Ratio--0.4300.379+13%0.140+207%0.156+176%0.156+176%
Dividend Per Share---0.081-100%-0%0.019-100%0.019-100%
Eps---0.349-0.288-17%-0.271-22%-0.246-30%-0.246-30%
Free Cash Flow Per Share---0.301-0.287-5%-0.235-22%-0.209-31%-0.209-31%
Free Cash Flow To Equity Per Share---0.0980.223-144%0.337-129%0.189-152%0.189-152%
Gross Profit Margin--1.0061.002+0%1.000+1%1.000+1%1.000+1%
Intrinsic Value_10Y_max---15.449--------
Intrinsic Value_10Y_min---13.172--------
Intrinsic Value_1Y_max---1.046--------
Intrinsic Value_1Y_min---1.027--------
Intrinsic Value_3Y_max---3.525--------
Intrinsic Value_3Y_min---3.357--------
Intrinsic Value_5Y_max---6.465--------
Intrinsic Value_5Y_min---5.968--------
Market Cap456495080.000+42%263148720.000305153680.000-14%194427370.000+35%488834538.824-46%488834538.824-46%
Net Profit Margin----0%-0%-0%-0%
Operating Margin----0%-0%-0%-0%
Operating Ratio----0%-0%-0%-0%
Pb Ratio3.250+42%1.8732.544-26%1.608+16%3.512-47%3.512-47%
Pe Ratio-5.297-73%-3.054-4.389+44%-2.993-2%-8.203+169%-8.203+169%
Price Per Share7.390+42%4.2604.940-14%3.148+35%7.914-46%7.914-46%
Price To Free Cash Flow Ratio-6.138-73%-3.538-4.358+23%-3.337-6%-10.046+184%-10.046+184%
Price To Total Gains Ratio-23.132-73%-13.33553.678-125%-6.724-50%-17.856+34%-17.856+34%
Quick Ratio--23.35421.911+7%17.359+35%22.246+5%22.246+5%
Return On Assets---0.107-0.101-5%-0.119+11%-0.111+4%-0.111+4%
Return On Equity---0.153-0.140-8%-0.136-11%-0.112-27%-0.112-27%
Total Gains Per Share---0.3190.171-287%0.037-965%0.153-309%0.153-309%
Usd Book Value--140479000.000127408000.000+10%124144750.000+13%108366117.647+30%108366117.647+30%
Usd Book Value Change Per Share---0.3190.089-457%0.037-965%0.134-339%0.134-339%
Usd Book Value Per Share--2.2742.063+10%2.010+13%1.754+30%1.754+30%
Usd Dividend Per Share---0.081-100%-0%0.019-100%0.019-100%
Usd Eps---0.349-0.288-17%-0.271-22%-0.246-30%-0.246-30%
Usd Free Cash Flow---18592000.000-17743250.000-5%-14542750.000-22%-12916058.824-31%-12916058.824-31%
Usd Free Cash Flow Per Share---0.301-0.287-5%-0.235-22%-0.209-31%-0.209-31%
Usd Free Cash Flow To Equity Per Share---0.0980.223-144%0.337-129%0.189-152%0.189-152%
Usd Market Cap456495080.000+42%263148720.000305153680.000-14%194427370.000+35%488834538.824-46%488834538.824-46%
Usd Price Per Share7.390+42%4.2604.940-14%3.148+35%7.914-46%7.914-46%
Usd Profit---21544000.000-17499250.000-19%-16314000.000-24%-14990882.353-30%-14990882.353-30%
Usd Revenue----0%-0%-0%-0%
Usd Total Gains Per Share---0.3190.171-287%0.037-965%0.153-309%0.153-309%
 EOD+5 -3MRQTTM+8 -24YOY+12 -185Y+10 -2210Y+10 -22

4.2. Fundamental Score

Let's check the fundamental score of Inozyme Pharma Inc based on Penke's default stock scanner.

Penke's Stock Scanner

  
  
IndicatorConditionValue
Price to Earnings Ratio (EOD)Between0-15-5.297
Price to Book Ratio (EOD)Between0-13.250
Net Profit Margin (MRQ)Greater than00.000
Operating Margin (MRQ)Greater than00.000
Quick Ratio (MRQ)Greater than123.354
Current Ratio (MRQ)Greater than113.363
Debt to Asset Ratio (MRQ)Less than10.301
Debt to Equity Ratio (MRQ)Less than10.430
Return on Equity (MRQ)Greater than0.15-0.153
Return on Assets (MRQ)Greater than0.05-0.107
Total4/10 (40.0%)

4.3. Technical Score

Let's check the technical score of Inozyme Pharma Inc based on Penke's default Symbol scanner.

Penke's Symbol Scanner

  
  
IndicatorConditionValue
RsiGreater than5070.617
Ma 20Greater thanMa 506.120
Ma 50Greater thanMa 1005.669
Ma 100Greater thanMa 2004.753
OpenGreater thanClose6.920
Total3/5 (60.0%)



Reversals in quarterly reports

I have detected a reversal (positive to negative, negative to positive) in the following values of the quarterly reports.

 2022-12-312023-03-312023-06-302023-09-302023-12-31
Net Debt  -26,1373,774-22,36315,635-6,728-6,067-12,79524,79912,004



Latest Balance Sheet

Balance Sheet of 2023-12-31. Currency in USD. All numbers in thousands.

Summary
Total Assets200,847
Total Liabilities60,368
Total Stockholder Equity140,479
 As reported
Total Liabilities 60,368
Total Stockholder Equity+ 140,479
Total Assets = 200,847

Assets

Total Assets200,847
Total Current Assets196,250
Long-term Assets4,597
Total Current Assets
Cash And Cash Equivalents 34,588
Short-term Investments 154,001
Net Receivables 385
Other Current Assets 7,276
Total Current Assets  (as reported)196,250
Total Current Assets  (calculated)196,250
+/-0
Long-term Assets
Property Plant Equipment 2,592
Long-term Assets Other 1,694
Long-term Assets  (as reported)4,597
Long-term Assets  (calculated)4,286
+/- 311

Liabilities & Shareholders' Equity

Total Current Liabilities14,686
Long-term Liabilities45,682
Total Stockholder Equity140,479
Total Current Liabilities
Short-term Debt 910
Accounts payable 1,166
Other Current Liabilities 12,610
Total Current Liabilities  (as reported)14,686
Total Current Liabilities  (calculated)14,686
+/-0
Long-term Liabilities
Long term Debt 44,769
Capital Lease Obligations Min Short Term Debt913
Long-term Liabilities  (as reported)45,682
Long-term Liabilities  (calculated)45,682
+/-0
Total Stockholder Equity
Common Stock6
Retained Earnings -285,930
Accumulated Other Comprehensive Income 41
Other Stockholders Equity 426,362
Total Stockholder Equity (as reported)140,479
Total Stockholder Equity (calculated)140,479
+/-0
Other
Capital Stock6
Cash and Short Term Investments 188,589
Common Stock Shares Outstanding 61,769
Liabilities and Stockholders Equity 200,847
Net Debt 12,004
Net Invested Capital 185,248
Net Working Capital 181,564
Property Plant and Equipment Gross 5,005
Short Long Term Debt Total 46,592



Balance Sheet

Currency in USD. All numbers in thousands.

 Trend2023-12-312023-09-302023-06-302023-03-312022-12-312022-09-302022-06-302022-03-312021-12-312021-09-302021-06-302021-03-312020-12-312020-09-302020-06-302020-03-312019-12-312019-09-302019-06-302019-03-31
> Total Assets 
0
0
0
47,944
75,736
68,511
178,993
169,363
158,915
148,259
137,746
123,541
108,931
161,989
154,021
139,195
141,796
150,929
205,702
200,847
200,847205,702150,929141,796139,195154,021161,989108,931123,541137,746148,259158,915169,363178,99368,51175,73647,944000
   > Total Current Assets 
0
0
0
47,460
74,963
64,660
163,977
150,979
148,041
140,962
130,579
115,342
100,583
153,748
145,926
131,393
134,148
143,588
200,856
196,250
196,250200,856143,588134,148131,393145,926153,748100,583115,342130,579140,962148,041150,979163,97764,66074,96347,460000
       Cash And Cash Equivalents 
0
0
0
31,605
55,637
50,863
59,858
28,040
16,486
26,239
27,229
23,316
31,943
62,620
44,044
32,915
49,024
40,845
46,895
34,588
34,58846,89540,84549,02432,91544,04462,62031,94323,31627,22926,23916,48628,04059,85850,86355,63731,605000
       Short-term Investments 
0
0
0
15,527
18,903
13,004
99,644
119,657
128,600
111,225
98,054
88,485
65,830
88,860
97,408
94,951
81,906
99,402
145,547
154,001
154,001145,54799,40281,90694,95197,40888,86065,83088,48598,054111,225128,600119,65799,64413,00418,90315,527000
       Net Receivables 
0
0
0
104
44
82
252
155
122
95
73
62
48
106
96
115
0
0
0
385
38500011596106486273951221552528244104000
       Other Current Assets 
0
0
0
224
379
711
4,223
3,127
2,833
3,403
5,223
92,026
2,762
2,268
4,378
3,527
3,218
3,341
8,414
7,276
7,2768,4143,3413,2183,5274,3782,2682,76292,0265,2233,4032,8333,1274,223711379224000
   > Long-term Assets 
0
0
0
484
773
3,851
15,016
18,384
10,874
7,297
7,167
8,199
8,348
8,241
8,095
7,802
7,648
7,341
4,846
4,597
4,5974,8467,3417,6487,8028,0958,2418,3488,1997,1677,29710,87418,38415,0163,851773484000
       Property Plant Equipment 
0
0
0
298
374
846
2,455
2,648
5,029
4,859
4,743
4,436
4,184
4,052
3,931
3,638
3,484
3,169
2,840
2,592
2,5922,8403,1693,4843,6383,9314,0524,1844,4364,7434,8595,0292,6482,455846374298000
       Long Term Investments 
0
0
0
0
0
0
12,207
12,199
2,548
0
0
0
0
0
0
0
0
0
0
0
000000000002,54812,19912,207000000
       Other Assets 
0
0
0
0
399
3,005
354
15,736
3,297
2,438
2,424
3,763
4,164
4,189
4,164
0
0
4,172
0
12
1204,172004,1644,1894,1643,7632,4242,4383,29715,7363543,0053990000
> Total Liabilities 
0
0
0
81,163
4,909
118,530
11,077
11,260
10,026
9,985
11,772
14,273
14,702
12,813
19,241
20,801
38,449
45,336
45,489
60,368
60,36845,48945,33638,44920,80119,24112,81314,70214,27311,7729,98510,02611,26011,077118,5304,90981,163000
   > Total Current Liabilities 
0
0
0
3,236
4,909
6,727
9,814
9,973
6,832
6,972
8,943
11,633
12,260
10,573
13,133
14,715
12,581
12,081
12,275
14,686
14,68612,27512,08112,58114,71513,13310,57312,26011,6338,9436,9726,8329,9739,8146,7274,9093,236000
       Short-term Debt 
0
0
0
0
0
0
0
0
672
691
711
731
752
773
794
816
839
862
886
910
91088686283981679477375273171169167200000000
       Accounts payable 
0
0
0
901
1,569
1,399
3,665
3,069
1,709
796
626
2,394
2,200
1,339
1,391
2,544
1,815
2,014
2,006
1,166
1,1662,0062,0141,8152,5441,3911,3392,2002,3946267961,7093,0693,6651,3991,569901000
       Other Current Liabilities 
0
0
0
2,335
3,340
5,328
6,149
6,904
4,451
5,485
7,606
8,508
9,308
4,651
10,948
7,545
9,927
9,205
9,383
12,610
12,6109,3839,2059,9277,54510,9484,6519,3088,5087,6065,4854,4516,9046,1495,3283,3402,335000
   > Long-term Liabilities 
0
0
0
77,927
0
111,803
1,263
1,287
3,194
3,013
2,829
2,640
2,442
2,240
6,108
6,086
25,868
33,255
33,214
45,682
45,68233,21433,25525,8686,0866,1082,2402,4422,6402,8293,0133,1941,2871,263111,803077,927000
       Long term Debt Total 
0
0
0
0
0
0
0
0
0
0
0
0
0
0
4,073
4,139
24,219
31,877
0
0
0031,87724,2194,1394,07300000000000000
       Other Liabilities 
0
0
0
0
0
238
1,263
1,287
0
0
0
0
0
0
0
0
0
0
0
0
0000000000001,2871,26323800000
       Deferred Long Term Liability 
0
0
0
0
269
2,650
0
0
0
0
0
0
0
0
0
0
0
0
0
0
000000000000002,6502690000
> Total Stockholder Equity
0
0
0
-33,219
70,827
-50,019
167,916
158,103
148,889
138,274
125,974
109,268
94,229
149,176
134,780
118,394
103,379
105,593
160,213
140,479
140,479160,213105,593103,379118,394134,780149,17694,229109,268125,974138,274148,889158,103167,916-50,01970,827-33,219000
   Common Stock
0
0
0
0
1
-44,657
2
2
2
2
2
2
2
4
4
4
4
5
6
6
66544442222222-44,65710000
   Retained Earnings Total Equity00-247,748-232,165-214,761-196,217-179,845-164,584-147,700-128,946-114,666-102,126-91,0760000000
   Accumulated Other Comprehensive Income 
0
0
0
5
28
13
-178,993
2
12
18
3
18
-129
-397
-477
-205
-36
51
-78
41
41-7851-36-205-477-397-12918318122-178,99313285000
   Capital Surplus 
0
0
0
0
1,561
0
0
249,175
251,001
252,920
254,915
256,948
258,940
329,414
331,470
333,356
335,544
353,285
0
0
00353,285335,544333,356331,470329,414258,940256,948254,915252,920251,001249,175001,5610000
   Treasury Stock00000000000000000000
   Other Stockholders Equity 
0
0
0
1,428
130,947
1,831
247,872
249,175
251,001
252,920
254,915
256,948
258,940
329,414
331,470
333,356
335,576
353,285
424,671
426,362
426,362424,671353,285335,576333,356331,470329,414258,940256,948254,915252,920251,001249,175247,8721,831130,9471,428000



Balance Sheet

Currency in USD. All numbers in thousands.




Cash Flow

Currency in USD. All numbers in thousands.




Income Statement

Currency in USD. All numbers in thousands.


Latest Income Statement (annual, 2023-12-31)

Gross Profit (+$)
totalRevenue0
Cost of Revenue-1,294
Gross Profit-1,294-1,294
 
Operating Income (+$)
Gross Profit-1,294
Operating Expense-74,351
Operating Income-75,645-75,645
 
Operating Expense (+$)
Research Development54,047
Selling General Administrative20,798
Selling And Marketing Expenses494
Operating Expense74,35175,339
 
Net Interest Income (+$)
Interest Income4,069
Interest Expense-3,333
Other Finance Cost-3,333
Net Interest Income4,069
 
Pretax Income (+$)
Operating Income-75,645
Net Interest Income4,069
Other Non-Operating Income Expenses0
Income Before Tax (EBT)-71,169-80,121
EBIT - interestExpense = -78,978
-71,169
-67,836
Interest Expense3,333
Earnings Before Interest and Taxes (EBIT)-75,645-67,836
Earnings Before Interest and Taxes (EBITDA)-74,351
 
After tax Income (+$)
Income Before Tax-71,169
Tax Provision-0
Net Income From Continuing Ops-68,169-71,169
Net Income-71,169
Net Income Applicable To Common Shares0
 
Non-recurring Events
Discontinued Operations0
Extraordinary Items0
Effect of Accounting Charges0
Other Items0
Non Recurring0
Other Operating Expenses75,645
Total Other Income/Expenses Net4,476-4,069
 

Technical Analysis of Inozyme
The psychology behind the price

Technical indicators reflecting market sentiment and the collective psychology of you and other traders. Your emotions and other traders' emotions, such as fear and greed, play a significant role in driving price movements.

General trend

First of all, I'm going to put something in the back of your mind. One of the most stable factors that gives you more confidence as a trader: the general trend of Inozyme. The general trend of Inozyme is BULLISH with 85.7% confidence. It is very important for your mental being to use each indicator with this in mind. But beware, also the general trend flips once in a while! You can use moving averages to determine Inozyme's overall trend. For convenience I use the most commonly used moving averages: 20, 50, 100 & 200. Of course you can use other moving averages or other indicators to determine the trend.

Indicator phases

Some of the indicators I use have 3 zones: overbought, oversold and neutral. Transitions between these zones (market phases) provide valuable trading signals and insights. Expecially with the general trend mind, I use the highlighted phases:

Indicator zone transitionsBullish trend (85.7%) Bearish trend (-85.7%)
Overbought to neutralBullish pullback=Bearish reversal
Upper to lower neutralBullish correction=Bearish continuation
Nuetral to oversoldOversold=Oversold
Oversold to neutralBullish reversal=Bearish correction
Lower to upper neutralBullish continuation=Bearish pullback
Nuetral to overboughtOverbought=Overbought

1. Price Targets

1.1 Support & Resistance

Support and resistance are levels on a price chart that act as barriers or zones where the price of an asset tends to stop, reverse, or experience a significant amount of buying or selling pressure.

Support is a price level at which demand for an asset is strong enough to prevent the price from falling further.
Resistance is a price level at which selling pressure becomes significant enough to prevent the price of an asset from rising further.


Score

Let's take a look at the Support & Resistance of Inozyme Pharma Inc.

The long score for the Support & Resistance is 1/1.
The longshort score for the Support & Resistance is 1/(-1 +1).

  • Around support: The price is currently trading around a support level. This can be considered as a potential entry level. +1

The bullish price targets are: .

The bearish price targets are: 7.33 > 7.24 > 7.01.

Tweet this
Inozyme Pharma Inc Daily Support & Resistance Chart

2. Trend Indicators

2.1 Moving Averages

Shows the moving average of the selected period.

  • Moving averages are lagging trend indicators.
  • There are many types of moving averages.
  • Moving averages are also used within other indicators.

Score

Let's take a look at the Moving Averages of Inozyme Pharma Inc. The current mas is .

The long score for the Moving Averages is 13/14.
The longshort score for the Moving Averages is 12/(-14 +14).

  • MA 20 trending up: The MA 20 is trending up. +1
  • Close > MA 20: The price is above the MA 20. +1
  • MA 20 > MA 50: The MA 20 is higher than the MA 50. +1
  • MA 20 > MA 100: The MA 20 is higher than the MA 100. +1
  • MA 20 > MA 200: The MA 20 is higher than the MA 200. +1
  • MA 50 trending up: The MA 50 is trending up. +1
  • Close > MA 50: The price is above the MA 50. +1
  • MA 50 > MA 100: The MA 50 is higher than the MA 100. +1
  • MA 50 > MA 200: The MA 50 is higher than the MA 200. +1
  • MA 100 trending up: The MA 100 is trending up. +1
  • Close > MA 100: The price is above the MA 100. +1
  • MA 100 < MA 200: The MA 100 is lower than the MA 200. -1
  • MA 200 trending up: The MA 200 is trending up. +1
  • Close > MA 200: The price is above the MA 200. +1

Directionalities and relatives.

Moving AverageAmount of candlesTrendPrice +/-vs. MA 50vs. MA 100vs. MA 200
MA 2020
MA 5050-
MA 100100--
MA 200200---

Explanation: https://www.youtube.com/watch?v=xwW8h0lrQ-I

Inozyme Pharma Inc Daily Moving Averages Chart
2.2 Moving Average Convergence/Divergence (MACD)

Shows the momentum of the selected period based on two moving averages.

  • MACD is a lagging momentum indicator.
  • Uses two moving averages.
  • Can show buy or sell signals based on momentum.
  • Can show overbought. and oversold. levels.

Score

Let's take a look at the Moving Average Convergence/Divergence (MACD) of Inozyme Pharma Inc. The current macd is 0.23354808.

The long score for the Moving Average Convergence/Divergence (MACD) is 4/4.
The longshort score for the Moving Average Convergence/Divergence (MACD) is 4/(-4 +4).

  • MACD line > signal line: The MACD line is above the signal line, which indicates a bullish signal in the market. This means that the positive momentum is currently stronger than the average momentum, suggesting that buyers are more active than sellers, and there's a higher probability of the Inozyme price going up in the near term. +2
  • MACD > 0: The MACD is above the zero line (centerline), it indicates a bullish signal for Inozyme. This means that the short-term moving average is higher than the long-term moving average, signaling positive momentum and suggesting a higher likelihood of the Inozyme price continuing to rise in the near future. It indicates that buyers are gaining control, and there is optimism in the market, leading to potential price increases. +1
  • Trending up: The MACD line is trending up. This indicates that the short-term moving average is rising faster than the long-term moving average, suggesting positive momentum in the market. This signals that buyers are becoming more active and confident, leading to potential price increases as traders anticipate further gains and are willing to buy at higher prices. +1
Inozyme Pharma Inc Daily Moving Average Convergence/Divergence (MACD) ChartInozyme Pharma Inc Daily Moving Average Convergence/Divergence (MACD) Chart
2.3 Directional Movement Index (DMI)

The DMI is a collection of 3 indicators: +DI (Plus Direction Indicator), -DI (Minus Direction Indicator) and ADX (Average Directional Index). The ADX helps you determine the strength of a trend.


Score

Let's take a look at the Directional Movement Index (DMI) of Inozyme Pharma Inc. The current adx is 22.71.

The long score for the Directional Movement Index (DMI) is 2/7.
The longshort score for the Directional Movement Index (DMI) is 2/(-7 +7).

  • PLUS_ID > MINUS_DI: The +DI line is above the -DI line. This indicates a bullish signal in the market, as the positive directional movement is currently stronger than the negative directional movement, showing that buyers have the upper hand. Market psychology suggests that traders are optimistic, expecting further price increases, and are more willing to buy Inozyme shares, leading to potential upward momentum in its price. +1
  • PLUS_ID > MINUS_DI && ADX < 25 && ADX trending up: The ADX is below 25 and indicates a weak or no trend. However, the ADX is rising and a new bullish trend could be forming. +1
Inozyme Pharma Inc Daily Directional Movement Index (DMI) Chart
2.4 Parabolic SAR

Shows the current trend and potential entry and exit signals.

  • Parabolic SAR (stop and reverse) is a lagging trend indicator.
  • Shows the current trend.
  • Shows potential entry signals.
  • Shows  potential exit signals.
  • Can be used to place trailing stoplosses..

Score

Let's take a look at the Parabolic SAR of Inozyme Pharma Inc. The current sar is 5.54874.

The long score for the Parabolic SAR is 1/1.
The longshort score for the Parabolic SAR is 1/(-1 +1).

  • Close > SAR: The price is above the SAR. It's generally considered a bullish signal. +1
Inozyme Pharma Inc Daily Parabolic SAR Chart

3. Momentum Indicators

3.1 Relative Strength Index (RSI)

Measures the speed and change of price movements.

  • Leading momentum indicator, meaning the signals are instant.
  • Ranges between 0 and 100.
  • Above 70 is considered overbought.
  • Below 30 is considered oversold.
  • Above or below 50 can also be used to determine price trend or support and resistance.
  • RSI divergence looks at a deviation between RSI and price movement. Penketrading automatically calculates RSI divergences.
  • Can be used in many different ways

Score

Let's take a look at the Relative Strength Index (RSI) of Inozyme Pharma Inc. The current rsi is 70.62. The current phase is Overbought in bull market.

The long score for the Relative Strength Index (RSI) is 1/13.
The longshort score for the Relative Strength Index (RSI) is 0/(-13 +13).

  • Overbought in bull market: Short-term excessive buying, potential for pullback. Consider taking profits, be cautious of potential correction. -1
  • Trending up: The RSI is trending up. +1
Inozyme Pharma Inc Daily Relative Strength Index (RSI) ChartInozyme Pharma Inc Daily Relative Strength Index (RSI) Chart
3.2 Stochastic Oscillator

Compares a certain price to multiple prices ranging over time.

  • Leading momentum indicator, meaning the signals are instant.
  • Used to determine overbought and oversold areas much like the RSI.
  • Ranges between 0 and 100.
  • Above 80 is considered overbought.
  • Below 20 is considered oversold.
  • Consists of two lines named K and D.
  • K compares the highest high and lowest low on the selected price range.
  • The D line is a moving average of the K line.
  • Can be used to spot divergences

Score

Let's take a look at the Stochastic Oscillator of Inozyme Pharma Inc. The current phase is Overbought in bull market.

The long score for the Stochastic Oscillator is 6/6.
The longshort score for the Stochastic Oscillator is 6/(-6 +6).

  • STOCH > 50: The STOCH %K is above 50. There are more buyers than sellers. +1
  • STOCH > 80: The STOCH %K is above 80 and overbought. +2
  • STOCH %K line > STOCH %D line: The STOCH %K line is above the STOCH %D line, which indicates a bullish signal in the market. This means that the positive momentum is currently stronger than the average momentum, suggesting that buyers are more active than sellers, and there's a higher probability of the Inozyme price going up in the near term. +2
  • Trending up: The STOCH %K is trending up. +1
Inozyme Pharma Inc Daily Stochastic Oscillator ChartInozyme Pharma Inc Daily Stochastic Oscillator Chart
3.3 Commodity Channel Index (CCI)

Measures the difference between the current price and the historical average price.

  • Lagging or leading Momentum indicator
  • When the CCI is above zero, the price is above the historical average
  • When the CCI is below zero, the price is below the historical average
  • Used for spotting trends
    • If the CCI moves from negative or near zero to positive 100 that might indicate an uptrend
    • If the CCI moves from positive or near zero to negative -100 that might indicate a downtrend

Score

Let's take a look at the Commodity Channel Index (CCI) of Inozyme Pharma Inc. The current cci is 227.32.

The long score for the Commodity Channel Index (CCI) is 1/1.
The longshort score for the Commodity Channel Index (CCI) is 1/(-1 +1).

  • CCI > 100: The CCI is above 100, it indicates that the price is significantly above its average, suggesting a potential overbought condition. +1
Inozyme Pharma Inc Daily Commodity Channel Index (CCI) ChartInozyme Pharma Inc Daily Commodity Channel Index (CCI) Chart
3.4 Chande Momentum Oscillator (CMO)

Measures the difference between the sum of recent gains and the sum of recent losses. Then divides the result by the sum of all price movements in that period.

  • Lagging momentum indicator
  • Ranges between +100 and -100
  • Considered overbought above +50
  • Considered oversold below -50
  • It's possible to add a moving average that acts as a signal line

Score

Let's take a look at the Chande Momentum Oscillator (CMO) of Inozyme Pharma Inc. The current cmo is 53.30.

The long score for the Chande Momentum Oscillator (CMO) is 1/1.
The longshort score for the Chande Momentum Oscillator (CMO) is 1/(-1 +1).

  • CMO > 0: The CMO is above 0, the momentum of the price is positive, indicating a potential uptrend in the price. +1
Inozyme Pharma Inc Daily Chande Momentum Oscillator (CMO) ChartInozyme Pharma Inc Daily Chande Momentum Oscillator (CMO) Chart
3.5 Williams %R

 Shows the current price relative to the highest high over the last 14 days.
 

  • Lagging momentum indicator
  • Ranging between 0 and -100
  • Above -20 is considered overbought
  • Below -80 is considered oversold
  • Is prone to give false signals

Score

Let's take a look at the Williams %R of Inozyme Pharma Inc. The current willr is -8.09086147.

The long score for the Williams %R is 1/1.
The longshort score for the Williams %R is 1/(-1 +1).

  • WILLR > -20: The Williams %R is above -20. This indicates that the price is in overbought territory, suggesting a potential price correction or trend reversal to the downside. +1
Inozyme Pharma Inc Daily Williams %R ChartInozyme Pharma Inc Daily Williams %R Chart

4. Volatility Indicators

4.1 Bollinger Bands

Shows if the price is to high or to low relative to an average.

  • Lagging volatility indicator
  • Uses 3 bands: one upper, one lower and one in the middle
  • Works best when the middle band reflects an intermediate trend (MA20).
  • When the price is moving closer to the upper band, the market might be overbought
  • When the price is moving closer to the lower band, the market might be oversold 

Score

Let's take a look at the Bollinger Bands of Inozyme Pharma Inc.

Inozyme Pharma Inc Daily Bollinger Bands Chart
4.2 Average True Range (ATR)
Measures market volatility
  • Leading volatility indicator
  • Can be used to determine stop-loss positions
  • Calculated by:
    • Current high minus the current low
    • Current high minus the previous close
    • Current low minus the previous close
  • The larger the range of the candles, the greater the ATR value

Score

Let's take a look at the Average True Range (ATR) of Inozyme Pharma Inc. The current atr is 0.45659193.

Inozyme Pharma Inc Daily Average True Range (ATR) ChartInozyme Pharma Inc Daily Average True Range (ATR) Chart

5. Volume Indicators

5.1 On-Balance Volume (OBV)

 Measures market volatility

  • Leading momentum indicator
  • Calculation:
    • If the closing price is above the previous closing price: OBV = previous OBV + current volume
    • If the closing price is below the previous closing price: OBV = previous OBV - current volume
    • If the closing price is the same as the previous closing price than the OBV is the same.
  • Can be used to confirm price trends
  • Can be used with divergences

Score

Let's take a look at the On-Balance Volume (OBV) of Inozyme Pharma Inc. The current obv is 74,985,195.

Inozyme Pharma Inc Daily On-Balance Volume (OBV) ChartInozyme Pharma Inc Daily On-Balance Volume (OBV) Chart
5.2 Money Flow Index (MFI)

Measures the flow of money in and out of a security

  • Lagging momentum indicator
  • Looks like RSI but uses volume as an extra metric (RSI only considers price)
  • Above 80 is considered overbought
  • Below 20 is considered oversold
  • Can be used with divergences

Score

Let's take a look at the Money Flow Index (MFI) of Inozyme Pharma Inc. The current mfi is 72.12.

The long score for the Money Flow Index (MFI) is 1/2.
The longshort score for the Money Flow Index (MFI) is 1/(-2 +2).

  • MFI > 50: +1
Inozyme Pharma Inc Daily Money Flow Index (MFI) ChartInozyme Pharma Inc Daily Money Flow Index (MFI) Chart

6. Summary

6.1. Notifications

TypeNotificationDate
PenkeCurrently no notifications for Inozyme Pharma Inc.

6.2. Trading Signals

Below you will find trading signals as the indicator is commonly used. This doesn't mean you should use it that way. Learn from these, but don't use them blindly. I recommend using at least 4 indicators, 1 from each category: trend, momentum, volatility and volume.

DateIndicatorSignal
2023-11-03CMO LONG ENTRY SHORT CLOSEZero line crossover to upside
2023-11-06STOCH LONG EXITThe %K line crosses below the %D line.
CMO SHORT ENTRY LONG CLOSEZero line crossover to downside
2023-11-07STOCH SHORT EXITThe %K line crosses above the %D line.
CMO LONG ENTRY SHORT CLOSEZero line crossover to upside
WILLR LONG ENTRY SHORT CLOSE-20 crossover to upside
2023-11-08STOCH LONG EXITThe %K line crosses below the %D line.
CMO SHORT ENTRY LONG CLOSEZero line crossover to downside
2023-11-09SAR SHORT ENTRY LONG CLOSEThe price broke the SAR to the downside
2023-11-13CCI SHORT ENTRY LONG CLOSE-100 crossover to downside
2023-11-14STOCH SHORT EXITThe %K line crosses above the %D line.
CMO LONG ENTRY SHORT CLOSEZero line crossover to upside
ATR LONG ENTRY SHORT CLOSEPrice closed above (close + ATR).
2023-11-15DMI LONG ENTRY SHORT CLOSEThe +DI crossed the -DI to the upside. The trend is reversing to an up trend.
SAR LONG ENTRY SHORT CLOSEThe price broke the SAR to the upside.
CCI LONG ENTRY SHORT CLOSE100 crossover to upside
2023-11-20WILLR LONG ENTRY SHORT CLOSE-20 crossover to upside
BB SHORT ENTRY LONG CLOSEPrice closed above the lower band.
ATR LONG ENTRY SHORT CLOSEPrice closed above (close + ATR).
2023-11-21STOCH LONG EXITThe %K line crosses below the %D line.
2023-11-24STOCH SHORT EXITThe %K line crosses above the %D line.
WILLR LONG ENTRY SHORT CLOSE-20 crossover to upside
BB SHORT ENTRY LONG CLOSEPrice closed above the lower band.
2023-11-27STOCH LONG EXITThe %K line crosses below the %D line.
2023-11-30STOCH SHORT EXITThe %K line crosses above the %D line.
CCI LONG ENTRY SHORT CLOSE100 crossover to upside
WILLR LONG ENTRY SHORT CLOSE-20 crossover to upside
2023-12-05STOCH LONG EXITThe %K line crosses below the %D line.
2023-12-07STOCH SHORT EXITThe %K line crosses above the %D line.
2023-12-08STOCH LONG EXITThe %K line crosses below the %D line.
2023-12-11SAR SHORT ENTRY LONG CLOSEThe price broke the SAR to the downside
CMO SHORT ENTRY LONG CLOSEZero line crossover to downside
2023-12-12MACD SHORT ENTRY LONG CLOSEThe MACD line crosses below the signal line.
2023-12-13MACD LONG ENTRY SHORT CLOSEThe MACD line crosses above the signal line.
STOCH SHORT EXITThe %K line crosses above the %D line.
CMO LONG ENTRY SHORT CLOSEZero line crossover to upside
WILLR LONG ENTRY SHORT CLOSE-20 crossover to upside
ATR LONG ENTRY SHORT CLOSEPrice closed above (close + ATR).
2023-12-14SAR LONG ENTRY SHORT CLOSEThe price broke the SAR to the upside.
CCI LONG ENTRY SHORT CLOSE100 crossover to upside
2023-12-15STOCH LONG EXITThe %K line crosses below the %D line.
2023-12-18STOCH SHORT EXITThe %K line crosses above the %D line.
WILLR LONG ENTRY SHORT CLOSE-20 crossover to upside
BB SHORT ENTRY LONG CLOSEPrice closed above the lower band.
2023-12-20STOCH LONG EXITThe %K line crosses below the %D line.
ATR SHORT ENTRY LONG CLOSEPrice closed below (close - ATR).
2023-12-21STOCH SHORT EXITThe %K line crosses above the %D line.
2023-12-22CCI LONG ENTRY SHORT CLOSE100 crossover to upside
WILLR LONG ENTRY SHORT CLOSE-20 crossover to upside
BB SHORT ENTRY LONG CLOSEPrice closed above the lower band.
ATR LONG ENTRY SHORT CLOSEPrice closed above (close + ATR).
2023-12-28STOCH LONG EXITThe %K line crosses below the %D line.
2024-01-03MACD SHORT ENTRY LONG CLOSEThe MACD line crosses below the signal line.
2024-01-04SAR SHORT ENTRY LONG CLOSEThe price broke the SAR to the downside
2024-01-08MACD LONG ENTRY SHORT CLOSEThe MACD line crosses above the signal line.
SAR LONG ENTRY SHORT CLOSEThe price broke the SAR to the upside.
STOCH SHORT EXITThe %K line crosses above the %D line.
CCI LONG ENTRY SHORT CLOSE100 crossover to upside
WILLR LONG ENTRY SHORT CLOSE-20 crossover to upside
ATR LONG ENTRY SHORT CLOSEPrice closed above (close + ATR).
2024-01-10STOCH LONG EXITThe %K line crosses below the %D line.
2024-01-11MACD SHORT ENTRY LONG CLOSEThe MACD line crosses below the signal line.
2024-01-12CMO SHORT ENTRY LONG CLOSEZero line crossover to downside
2024-01-16SAR SHORT ENTRY LONG CLOSEThe price broke the SAR to the downside
WILLR SHORT ENTRY LONG CLOSE-80 crossover to downside
2024-01-17STOCH SHORT EXITThe %K line crosses above the %D line.
2024-01-19CMO LONG ENTRY SHORT CLOSEZero line crossover to upside
2024-01-24STOCH LONG EXITThe %K line crosses below the %D line.
2024-01-25MACD LONG ENTRY SHORT CLOSEThe MACD line crosses above the signal line.
STOCH SHORT EXITThe %K line crosses above the %D line.
CCI LONG ENTRY SHORT CLOSE100 crossover to upside
WILLR LONG ENTRY SHORT CLOSE-20 crossover to upside
2024-01-26SAR LONG ENTRY SHORT CLOSEThe price broke the SAR to the upside.
2024-01-29BB SHORT ENTRY LONG CLOSEPrice closed above the lower band.
ATR LONG ENTRY SHORT CLOSEPrice closed above (close + ATR).
2024-01-30STOCH LONG EXITThe %K line crosses below the %D line.
2024-01-31MFI LONG ENTRY SHORT CLOSE80 crossover to upside
2024-02-01STOCH SHORT EXITThe %K line crosses above the %D line.
2024-02-02RSI SHORT ENTRY LONG CLOSE70 crossover to downside
STOCH LONG EXITThe %K line crosses below the %D line.
ATR SHORT ENTRY LONG CLOSEPrice closed below (close - ATR).
2024-02-06STOCH SHORT EXITThe %K line crosses above the %D line.
2024-02-07STOCH LONG EXITThe %K line crosses below the %D line.
2024-02-08STOCH SHORT EXITThe %K line crosses above the %D line.
2024-02-09CCI LONG ENTRY SHORT CLOSE100 crossover to upside
WILLR LONG ENTRY SHORT CLOSE-20 crossover to upside
ATR LONG ENTRY SHORT CLOSEPrice closed above (close + ATR).
2024-02-13RSI SHORT ENTRY LONG CLOSE70 crossover to downside
STOCH LONG EXITThe %K line crosses below the %D line.
ATR SHORT ENTRY LONG CLOSEPrice closed below (close - ATR).
MFI SHORT ENTRY LONG CLOSE80 crossover to downside
2024-02-15STOCH SHORT EXITThe %K line crosses above the %D line.
2024-02-20STOCH LONG EXITThe %K line crosses below the %D line.
2024-02-21MACD SHORT ENTRY LONG CLOSEThe MACD line crosses below the signal line.
2024-02-22SAR SHORT ENTRY LONG CLOSEThe price broke the SAR to the downside
2024-02-23STOCH SHORT EXITThe %K line crosses above the %D line.
2024-02-26SAR LONG ENTRY SHORT CLOSEThe price broke the SAR to the upside.
CCI LONG ENTRY SHORT CLOSE100 crossover to upside
WILLR LONG ENTRY SHORT CLOSE-20 crossover to upside
BB SHORT ENTRY LONG CLOSEPrice closed above the lower band.
ATR LONG ENTRY SHORT CLOSEPrice closed above (close + ATR).
2024-02-27MACD LONG ENTRY SHORT CLOSEThe MACD line crosses above the signal line.
ATR LONG ENTRY SHORT CLOSEPrice closed above (close + ATR).
MFI LONG ENTRY SHORT CLOSE80 crossover to upside
2024-02-28RSI SHORT ENTRY LONG CLOSE70 crossover to downside
STOCH LONG EXITThe %K line crosses below the %D line.
2024-02-29MFI SHORT ENTRY LONG CLOSE80 crossover to downside
2024-03-01STOCH SHORT EXITThe %K line crosses above the %D line.
2024-03-04STOCH LONG EXITThe %K line crosses below the %D line.
2024-03-06MACD SHORT ENTRY LONG CLOSEThe MACD line crosses below the signal line.
SAR SHORT ENTRY LONG CLOSEThe price broke the SAR to the downside
2024-03-07STOCH SHORT EXITThe %K line crosses above the %D line.
2024-03-11DMI SHORT ENTRY LONG CLOSEThe +DI crossed the -DI to the downside. The trend is reversing to a down trend.
STOCH LONG EXITThe %K line crosses below the %D line.
CMO SHORT ENTRY LONG CLOSEZero line crossover to downside
WILLR SHORT ENTRY LONG CLOSE-80 crossover to downside
ATR SHORT ENTRY LONG CLOSEPrice closed below (close - ATR).
2024-03-13STOCH SHORT EXITThe %K line crosses above the %D line.
2024-03-14STOCH LONG EXITThe %K line crosses below the %D line.
WILLR SHORT ENTRY LONG CLOSE-80 crossover to downside
2024-03-15DMI LONG ENTRY SHORT CLOSEThe +DI crossed the -DI to the upside. The trend is reversing to an up trend.
STOCH SHORT EXITThe %K line crosses above the %D line.
2024-03-18CMO LONG ENTRY SHORT CLOSEZero line crossover to upside
2024-03-19STOCH LONG EXITThe %K line crosses below the %D line.
CMO SHORT ENTRY LONG CLOSEZero line crossover to downside
WILLR SHORT ENTRY LONG CLOSE-80 crossover to downside
2024-03-20STOCH SHORT EXITThe %K line crosses above the %D line.
CMO LONG ENTRY SHORT CLOSEZero line crossover to upside
2024-03-21CMO SHORT ENTRY LONG CLOSEZero line crossover to downside
2024-03-22STOCH LONG EXITThe %K line crosses below the %D line.
2024-03-25SAR LONG ENTRY SHORT CLOSEThe price broke the SAR to the upside.
STOCH SHORT EXITThe %K line crosses above the %D line.
CMO LONG ENTRY SHORT CLOSEZero line crossover to upside
ATR LONG ENTRY SHORT CLOSEPrice closed above (close + ATR).
2024-03-26MACD LONG ENTRY SHORT CLOSEThe MACD line crosses above the signal line.
CCI LONG ENTRY SHORT CLOSE100 crossover to upside
BB SHORT ENTRY LONG CLOSEPrice closed above the lower band.
ATR LONG ENTRY SHORT CLOSEPrice closed above (close + ATR).
2024-03-27WILLR LONG ENTRY SHORT CLOSE-20 crossover to upside
ATR LONG ENTRY SHORT CLOSEPrice closed above (close + ATR).

6.3. Candlestick Patterns

Inozyme Pharma Inc Daily Candlestick Chart
DateCandlestick Pattern

6.4. Technical Score

Let's check the technical score of Inozyme Pharma Inc based on Penke's default Symbol scanner.

Penke's Symbol Scanner

  
  
IndicatorConditionValue
RsiGreater than5070.617
Ma 20Greater thanMa 506.120
Ma 50Greater thanMa 1005.669
Ma 100Greater thanMa 2004.753
OpenGreater thanClose6.920
Total3/5 (60.0%)
Penke

Good job! You gained 25 XP and 0   0   10 . What's next:

  • Share my analysis of Inozyme with someone you think should read this too:
  • Are you bullish or bearish on Inozyme? Let me know what you think in the comments.
  • Do you want an email if I find something interesting about Inozyme? Add an email alert using the form below.
  • Join the community if you want to keep your earnings and track your progress: Join the community
  • Is this analysis useful to you? Support me via But Me a Coffee. I'll analyze the stock market faster for you!

Get notifications about Inozyme Pharma Inc

I send you an email if I find something interesting about Inozyme Pharma Inc.


Comments

How you think about this?

Leave a comment

Stay informed about Inozyme Pharma Inc.

Receive notifications about Inozyme Pharma Inc in your mailbox!